Ibrutinib in CLL/SLL: From bench to bedside (Review)
- Authors:
- Fuming Zi
- Li Yu
- Qingzhi Shi
- Aiping Tang
- Jing Cheng
-
Affiliations: Department of Hematology, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, P.R. China - Published online on: October 10, 2019 https://doi.org/10.3892/or.2019.7364
- Pages: 2213-2227
This article is mentioned in:
Abstract
 |
 |
|
Niiro H and Clark EA: Regulation of B-cell fate by antigen-receptor signals. Nat Rev Immunol. 2:945–956. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Bojarczuk K, Bobrowicz M, Dwojak M, Miazek N, Zapala P, Bunes A, Siernicka M, Rozanska M and Winiarska M: B-cell receptor signaling in the pathogenesis of lymphoid malignancies. Blood Cells Mol Dis. 55:255–265. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Mohamed AJ, Vargas L, Nore BF, Backesjo CM, Christensson B and Smith CI: Nucleocytoplasmic shuttling of Bruton's tyrosine kinase. J Biol Chem. 275:40614–40619. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Hendriks RW, Yuvaraj S and Kil LP: Targeting Bruton's tyrosine kinase in B cell malignancies. Nat Rev Cancer. 14:219–232. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Honigberg LA, Smith AM, Sirisawad M, Verner E, Loury D, Chang B, Li S, Pan Z, Thamm DH, Miller RA, et al: The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci USA. 107:13075–13080. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Small S: Ibrutinib approved for the treatment of mantle cell lymphoma. Clin Adv Hematol Oncol. 11:8082013. | |
|
Dangi-Garimella S: FDA grants accelerated approval for ibrutinib for CLL. Am J Manag Care. 20:E102014.PubMed/NCBI | |
|
Raedler LA: Imbruvica (Ibrutinib): First drug approved for the treatment of patients with Waldenströms macroglobulinemia. Am Health Drug Benefits. 9:(Spec Feature). 89–92. 2016.PubMed/NCBI | |
|
Packard TA and Cambier JC: B lymphocyte antigen receptor signaling: Initiation, amplification, and regulation. F1000Prime Rep. 5:402013. View Article : Google Scholar : PubMed/NCBI | |
|
Rickert RC: New insights into pre-BCR and BCR signalling with relevance to B cell malignancies. Nat Rev Immunol. 13:578–591. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Kaur V and Swami A: Ibrutinib in CLL: A focus on adverse events, resistance, and novel approaches beyond ibrutinib. Ann Hematol. 96:1175–1184. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Wang Y, Zhang LL, Champlin RE and Wang ML: Targeting Bruton's tyrosine kinase with ibrutinib in B-cell malignancies. Clin Pharmacol Ther. 97:455–468. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Vetrie D, Vorechovský I, Sideras P, Holland J, Davies A, Flinter F, Hammarström L, Kinnon C, Levinsky R, Bobrow M, et al: The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases. Nature. 361:226–233. 1993. View Article : Google Scholar : PubMed/NCBI | |
|
Bruton OC: Agammaglobulinemia. Pediatrics. 9:722–728. 1952.PubMed/NCBI | |
|
Hagemann TL, Chen Y, Rosen FS and Kwan SP: Genomic organization of the Btk gene and exon scanning for mutations in patients with X-linked agammaglobulinemia. Hum Mol Genet. 3:1743–1749. 1994. View Article : Google Scholar : PubMed/NCBI | |
|
Cheng S, Ma J, Guo A, Lu P, Leonard JP, Coleman M, Liu M, Buggy JJ, Furman RR and Wang YL: BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity. Leukemia. 28:649–657. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Berglöf A, Hamasy A, Meinke S, Palma M, Krstic A, Månsson R, Kimby E, Österborg A and Smith CI: Targets for ibrutinib beyond B cell malignancies. Scand J Immunol. 82:208–217. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Bradshaw JM: The Src, Syk, and Tec family kinases: Distinct types of molecular switches. Cell Signal. 22:1175–1184. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Pan Z, Scheerens H, Li SJ, Schultz BE, Sprengeler PA, Burrill LC, Mendonca RV, Sweeney MD, Scott KC, Grothaus PG, et al: Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase. ChemMedChem. 2:58–61. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Kawakami Y, Kitaura J, Hata D, Yao L and Kawakami T: Functions of Bruton's tyrosine kinase in mast and B cells. J Leukoc Biol. 65:286–290. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Khare A, Viswanathan B, Gund R, Jain N, Ravindran B, George A, Rath S and Bal V: Role of Bruton's tyrosine kinase in macrophage apoptosis. Apoptosis. 16:334–346. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Bao Y, Zheng J, Han C, Jin J, Han H, Liu Y, Lau YL, Tu W and Cao X: Tyrosine kinase Btk is required for NK cell activation. J Biol Chem. 287:23769–23778. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Stiff A, Trikha P, Wesolowski R, Kendra K, Hsu V, Uppati S, McMichael E, Duggan M, Campbell A, Keller K, et al: Myeloid-derived suppressor cells express Bruton's tyrosine kinase and can be depleted in tumor-bearing hosts by ibrutinib treatment. Cancer Res. 76:2125–2136. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Satterthwaite AB, Li Z and Witte ON: Btk function in B cell development and response. Semin Immunol. 10:309–316. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Küppers R: Mechanisms of B-cell lymphoma pathogenesis. Nat Rev Cancer. 5:251–262. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Buggy JJ and Elias L: Bruton tyrosine kinase (BTK) and its role in B-cell malignancy. Int Rev Immunol. 31:119–132. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Cinar M, Hamedani F, Mo Z, Cinar B, Amin HM and Alkan S: Bruton tyrosine kinase is commonly overexpressed in mantle cell lymphoma and its attenuation by Ibrutinib induces apoptosis. Leuk Res. 37:1271–1277. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Goodman PA, Wood CM, Vassilev AO, Mao C and Uckun FM: Defective expression of Bruton's tyrosine kinase in acute lymphoblastic leukemia. Leuk Lymphoma. 44:1011–1018. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Pal Singh S, Dammeijer F and Hendriks RW: Role of Bruton's tyrosine kinase in B cells and malignancies. Mol Cancer. 17:572018. View Article : Google Scholar : PubMed/NCBI | |
|
Brown JR: Ibrutinib (PCI-32765), the first BTK (Bruton's tyrosine kinase) inhibitor in clinical trials. Curr Hematol Malig Rep. 8:1–6. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Singh J, Petter RC and Kluge AF: Targeted covalent drugs of the kinase family. Curr Opin Chem Biol. 14:475–480. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Grabinski N and Ewald F: Ibrutinib (ImbruvicaTM) potently inhibits ErbB receptor phosphorylation and cell viability of ErbB2-positive breast cancer cells. Invest New Drugs. 32:1096–1104. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Zucha MA, Wu AT, Lee WH, Wang LS, Lin WW, Yuan CC and Yeh CT: Bruton's tyrosine kinase (Btk) inhibitor ibrutinib suppresses stem-like traits in ovarian cancer. Oncotarget. 6:13255–13268. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Wang JD, Chen XY, Ji KW and Tao F: Targeting Btk with ibrutinib inhibit gastric carcinoma cells growth. Am J Transl Res. 8:3003–3012. 2016.PubMed/NCBI | |
|
Gao W, Wang M, Wang L, Lu H, Wu S, Dai B, Ou Z, Zhang L, Heymach JV, Gold KA, et al: Selective antitumor activity of ibrutinib in EGFR-mutant non-small cell lung cancer cells. J Natl Cancer Inst. 106:dju2042014.doi: 10.1093/jnci/dju204. View Article : Google Scholar : PubMed/NCBI | |
|
Wei L, Su YK, Lin CM, Chao TY, Huang SP, Huynh TT, Jan HJ, Whang-Peng J, Chiou JF, Wu AT, et al: Preclinical investigation of ibrutinib, a Bruton's kinase tyrosine (Btk) inhibitor, in suppressing glioma tumorigenesis and stem cell phenotypes. Oncotarget. 7:69961–69975. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Wang J, Liu X, Hong Y, Wang S, Chen P, Gu A, Guo X and Zhao P: Ibrutinib, a Bruton's tyrosine kinase inhibitor, exhibits antitumoral activity and induces autophagy in glioblastoma. J Exp Clin Cancer Res. 36:962017. View Article : Google Scholar : PubMed/NCBI | |
|
Rushworth SA, Pillinger G, Abdul-Aziz A, Piddock R, Shafat MS, Murray MY, Zaitseva L, Lawes MJ, MacEwan DJ and Bowles KM: Activity of Bruton's tyrosine-kinase inhibitor ibrutinib in patients with CD117-positive acute myeloid leukaemia: A mechanistic study using patient-derived blast cells. Lancet Haematol. 2:e204–e211. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Kim E, Hurtz C, Koehrer S, Wang Z, Balasubramanian S, Chang BY, Müschen M, Davis RE and Burger JA: Ibrutinib inhibits pre-BCR+ B-cell acute lymphoblastic leukemia progression by targeting BTK and BLK. Blood. 129:1155–1165. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Deeks ED: Ibrutinib: A Review in chronic lymphocytic leukaemia. Drugs. 77:225–236. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
de Zwart L, Snoeys J, De Jong J, Sukbuntherng J, Mannaert E and Monshouwer M: Ibrutinib dosing strategies based on interaction potential of CYP3A4 perpetrators using physiologically based pharmacokinetic modeling. Clin Pharmacol Ther. 100:548–557. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Finnes HD, Chaffee KG, Call TG, Ding W, Kenderian SS, Bowen DA, Conte M, McCullough KB, Merten JA, Bartoo GT, et al: Pharmacovigilance during ibrutinib therapy for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in routine clinical practice. Leuk Lymphoma. 58:1376–1383. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
FDA U: Imbruvica (ibrutinib) capsules: US prescribing information. http://www.fda.gov.2016 | |
|
Ltd J-C: Imbruvica 140 mg hard capsules. https://www.medicines.org.uk/emc/medicine/293832018 | |
|
Herman SEM, Gordon AL, Hertlein E, Ramanunni A, Zhang X, Jaglowski S, Flynn J, Jones J, Blum KA, Buggy JJ, et al: Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood. 117:6287–6296. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Woyach JA, Bojnik E, Ruppert AS, Stefanovski MR, Goettl VM, Smucker KA, Smith LL, Dubovsky JA, Towns WH, MacMurray J, et al: Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL). Blood. 123:1207–1213. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Herman SE, Sun X, McAuley EM, Hsieh MM, Pittaluga S, Raffeld M, Liu D, Keyvanfar K, Chapman CM, Chen J, et al: Modeling tumor-host interactions of chronic lymphocytic leukemia in xenografted mice to study tumor biology and evaluate targeted therapy. Leukemia. 27:2311–2321. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
OBrien S, Furman RR, Coutre SE, Sharman JP, Burger JA, Blum KA, Grant B, Richards DA, Coleman M, Wierda WG, et al: Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: An open-label, multicentre, phase 1b/2 trial. Lancet Oncol. 15:48–58. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, Ghia P, Bairey O, Hillmen P, Bartlett NL, Li J, et al RESONATE-2 Investigators, : Ibrutinib as initial yherapy for patients with chronic lymphocytic leukemia. N Engl J Med. 373:2425–2437. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Shanafelt TD, Wang V, Kay NE, Hanson CA, OBrien SM, Barrientos JC, Erba HP, Stone RM, Litzow MR and Tallman MS: A Randomized phase III study of ibrutinib (PCI-32765)-based therapy vs. standard fludarabine, cyclophosphamide, and rituximab (FCR) chemoimmunotherapy in untreated younger patients with chronic lymphocytic leukemia (CLL): A trial of the ECOG-ACRIN Cancer Research Group (E1912). Blood. 132:LBA–4-LBA-4. 2018. View Article : Google Scholar | |
|
Woyach JA, Ruppert AS, Heerema NA, Zhao W, Booth AM, Ding W, Bartlett NL, Brander DM, Barr PM, Rogers KA, et al: Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N Engl J Med. 379:2517–2528. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Moreno C, Greil R, Demirkan F, Tedeschi A, Anz B, Larratt L, Simkovic M, Samoilova O, Novak J, Ben-Yehuda D, et al: Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): A multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 20:43–56. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Advani RH, Buggy JJ, Sharman JP, Smith SM, Boyd TE, Grant B, Kolibaba KS, Furman RR, Rodriguez S, Chang BY, et al: Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol. 31:88–94. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, Grant B, Sharman JP, Coleman M, Wierda WG, et al: Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 369:32–42. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Byrd JC, Brown JR, OBrien S, Barrientos JC, Kay NE, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, et al RESONATE Investigators, : Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 371:213–223. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Byrd JC, Furman RR, Coutre SE, Burger JA, Blum KA, Coleman M, Wierda WG, Jones JA, Zhao W, Heerema NA, et al: Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood. 125:2497–2506. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Coutré SE, Furman RR, Flinn IW, Burger JA, Blum K, Sharman J, Jones J, Wierda W, Zhao W, Heerema NA, et al: Extended treatment with single-agent ibrutinib at the 420 mg dose leads to durable responses in chronic lymphocytic leukemia/small lymphocytic lymphoma. Clin Cancer Res. 23:1149–1155. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
OBrien S, Furman RR, Coutre S, Flinn IW, Burger JA, Blum K, Sharman J, Wierda W, Jones J, Zhao W, et al: Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: A 5-year experience. Blood. 131:1910–1919. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Farooqui MZ, Valdez J, Martyr S, Aue G, Saba N, Niemann CU, Herman SE, Tian X, Marti G, Soto S, et al: Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: A phase 2, single-arm trial. Lancet Oncol. 16:169–176. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Ahn IE, Farooqui MZH, Tian X, Valdez J, Sun C, Soto S, Lotter J, Housel S, Stetler-Stevenson M, Yuan CM, et al: Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study. Blood. 131:2357–2366. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
OBrien S, Jones JA, Coutre SE, Mato AR, Hillmen P, Tam C, Österborg A, Siddiqi T, Thirman MJ, Furman RR, et al: Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): A phase 2, open-label, multicentre study. Lancet Oncol. 17:1409–1418. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Jones J, Mato A, Coutre S, Byrd JC, Furman RR, Hillmen P, Osterborg A, Tam C, Stilgenbauer S, Wierda WG, et al: Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trials. Br J Haematol. 182:504–512. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Winqvist M, Asklid A, Andersson PO, Karlsson K, Karlsson C, Lauri B, Lundin J, Mattsson M, Norin S, Sandstedt A, et al: Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: Data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group. Haematologica. 101:1573–1580. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Mato AR, Nabhan C, Barr PM, Ujjani CS, Hill BT, Lamanna N, Skarbnik AP, Howlett C, Pu JJ, Sehgal AR, et al: Outcomes of CLL patients treated with sequential kinase inhibitor therapy: A real world experience. Blood. 128:2199–2205. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Ysebaert L, Aurran-Schleinitz T, Dartigeas C, Dilhuydy MS, Feugier P, Michallet AS, Tournilhac O, Dupuis J, Sinet P, Albrecht C, et al: Real-world results of ibrutinib in relapsed/refractory CLL in France: Early results on a large series of 428 patients. Am J Hematol. 92:E166–E168. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Mato AR, Hill BT, Lamanna N, Barr PM, Ujjani CS, Brander DM, Howlett C, Skarbnik AP, Cheson BD, Zent CS, et al: Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: Results from a multicenter study of 683 patients. Ann Oncol. 28:1050–1056. 2017.PubMed/NCBI | |
|
Hillmen P, Diels J, Healy N, Iraqi W, Aschan J and Wildgust M: Ibrutinib for chronic lymphocytic leukemia: International experience from a named patient program. Haematologica. 103:e204–e206. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
UK CLL Forum, . Ibrutinib for relapsed/refractory chronic lymphocytic leukemia: A UK and Ireland analysis of outcomes in 315 patients. Haematologica. 101:1563–1572. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Barr PM, Brown JR, Hillmen P, OBrien S, Barrientos JC, Reddy NM, Coutre S, Mulligan SP, Jaeger U, Furman RR, et al: Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL. Blood. 129:2612–2615. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Da Roit F, Engelberts PJ, Taylor RP, Breij EC, Gritti G, Rambaldi A, Introna M, Parren PW, Beurskens FJ and Golay J: Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: Implications for combination therapy. Haematologica. 100:77–86. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Hing ZA, Mantel R, Beckwith KA, Guinn D, Williams E, Smith LL, Williams K, Johnson AJ, Lehman AM, Byrd JC, et al: Selinexor is effective in acquired resistance to ibrutinib and synergizes with ibrutinib in chronic lymphocytic leukemia. Blood. 125:3128–3132. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Younes A, Thieblemont C, Morschhauser F, Flinn I, Friedberg JW, Amorim S, Hivert B, Westin J, Vermeulen J, Bandyopadhyay N, et al: Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: A non-randomised, phase 1b study. Lancet Oncol. 15:1019–1026. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Burger JA, Keating MJ, Wierda WG, Hartmann E, Hoellenriegel J, Rosin NY, de Weerdt I, Jeyakumar G, Ferrajoli A, Cardenas-Turanzas M, et al: Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: A single-arm, phase 2 study. Lancet Oncol. 15:1090–1099. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Jaglowski SM, Jones JA, Nagar V, Flynn JM, Andritsos LA, Maddocks KJ, Woyach JA, Blum KA, Grever MR, Smucker K, et al: Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: A phase 1b/2 study. Blood. 126:842–850. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Maddocks K, Christian B, Jaglowski S, Flynn J, Jones JA, Porcu P, Wei L, Jenkins C, Lozanski G, Byrd JC, et al: A phase 1/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed/refractory non-Hodgkin lymphoma. Blood. 125:242–248. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Sharman JP, Farber CM, Mahadevan D, Schreeder MT, Brooks HD, Kolibaba KS, Fanning S, Klein L, Greenwald DR, Sportelli P, et al: Ublituximab (TG-1101), a novel glycoengineered anti-CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: Results of a phase 2 trial. Br J Haematol. 176:412–420. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Cervantes-Gomez F, Lamothe B, Woyach JA, Wierda WG, Keating MJ, Balakrishnan K and Gandhi V: Pharmacological and protein profiling suggests venetoclax (ABT-199) as optimal partner with ibrutinib in chronic lymphocytic leukemia. Clin Cancer Res. 21:3705–3715. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Brown JR, Barrientos JC, Barr PM, Flinn IW, Burger JA, Tran A, Clow F, James DF, Graef T, Friedberg JW, et al: The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia. Blood. 125:2915–2922. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Chanan-Khan A, Cramer P, Demirkan F, Fraser G, Silva RS, Grosicki S, Pristupa A, Janssens A, Mayer J, Bartlett NL, et al HELIOS investigators, : Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): A randomised, double-blind, phase 3 study. Lancet Oncol. 17:200–211. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Nastoupil L, Lunning MA, Vose JM, Schreeder MT, Siddiqi T, Flowers CR, Cohen JB, Burger JA, Wierda WG, OBrien S, et al: Chemo-free triplet combination of TGR-1202, ublituximab and ibrutinib is well tolerated and highly active in patients with advanced CLL and NHL. Hematol Oncol. 35:112–113. 2017. View Article : Google Scholar | |
|
Ujjani C, Wang H, Skarbnik A, Trivedi N, Ramzi P, Khan N and Cheson BD: A phase 1 study of lenalidomide and ibrutinib in combination with rituximab in relapsed and refractory CLL. Blood Adv. 2:762–768. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Hershkovitz-Rokah O, Pulver D, Lenz G and Shpilberg O: Ibrutinib resistance in mantle cell lymphoma: Clinical, molecular and treatment aspects. Br J Haematol. 181:306–319. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Furman RR, Cheng S, Lu P, Setty M, Perez AR, Guo A, Racchumi J, Xu G, Wu H, Ma J, et al: Ibrutinib resistance in chronic lymphocytic leukemia. N Engl J Med. 370:2352–2354. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Woyach JA, Ruppert AS, Guinn D, Lehman A, Blachly JS, Lozanski A, Heerema NA, Zhao W, Coleman J, Jones D, et al: BTKC481S-mediated resistance to ibrutinib in chronic lymphocytic leukemia. J Clin Oncol. 35:1437–1443. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Ahn IE, Underbayev C, Albitar A, Herman SE, Tian X, Maric I, Arthur DC, Wake L, Pittaluga S, Yuan CM, et al: Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia. Blood. 129:1469–1479. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Ahn IE, Tian X, Albitar M, Herman SEM, Cook EM, Soto S, Ma W, Ipe D, Tsao LC, Cheng M, et al: Validation of clinical prognostic models and integration of genetic biomarkers of drug resistance in CLL patients treated with ibrutinib. Blood. 132:186. 2018. View Article : Google Scholar | |
|
Quinquenel A, Fornecker LM, Letestu R, Ysebaert L, Fleury C, Lazarian G, Dilhuydy MS, Nollet D, Guieze R, Feugier P, et al: High prevalence of BTK mutations on ibrutinib therapy after 3 years of treatment in a real-life cohort of CLL patients: A study from the French Innovative Leukemia Organization (FILO) Group. Blood. 132:584. 2018. View Article : Google Scholar | |
|
Boissard F, Fournié JJ, Quillet-Mary A, Ysebaert L and Poupot M: Nurse-like cells mediate ibrutinib resistance in chronic lymphocytic leukemia patients. Blood Cancer J. 5:e3552015. View Article : Google Scholar : PubMed/NCBI | |
|
Borge M, Belén Almejún M, Podaza E, Colado A, Fernández Grecco H, Cabrejo M, Bezares RF, Giordano M and Gamberale R: Ibrutinib impairs the phagocytosis of rituximab-coated leukemic cells from chronic lymphocytic leukemia patients by human macrophages. Haematologica. 100:e140–e142. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Kohrt HE, Sagiv-Barfi I, Rafiq S, Herman SE, Butchar JP, Cheney C, Zhang X, Buggy JJ, Muthusamy N, Levy R, et al: Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity. Blood. 123:1957–1960. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Jacobson C, Kopp N, Layer JV, Redd RA, Tschuri S, Haebe S, van Bodegom D, Bird L, Christie AL, Christodoulou A, et al: HSP90 inhibition overcomes ibrutinib resistance in mantle cell lymphoma. Blood. 128:2517–2526. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Srour SA, Lee HJ, Nomie K, Ye H, Chen W, Oriabure O, Romaguera J and Wang ML: Novel chemotherapy-free combination regimen for ibrutinib-resistant mantle cell lymphoma. Br J Haematol. 181:561–564. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Brown JR, Moslehi J, OBrien S, Ghia P, Hillmen P, Cymbalista F, Shanafelt TD, Fraser G, Rule S, Kipps TJ, et al: Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials. Haematologica. 102:1796–1805. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Gustine JN, Meid K, Dubeau TE, Treon SP and Castillo JJ: Atrial fibrillation associated with ibrutinib in Waldenström macroglobulinemia. Am J Hematol. 91:E312–E313. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Farooqui M, Valdez J, Soto S, Bray A, Tian X and Wiestner A: Atrial fibrillation in CLL/SLL patients on ibrutinib. Blood. 126:2933. 2015. View Article : Google Scholar | |
|
Leong DP, Caron F, Hillis C, Duan A, Healey JS, Fraser G and Siegal D: The risk of atrial fibrillation with ibrutinib use: A systematic review and meta-analysis. Blood. 128:138–140. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
McMullen JR, Boey EJ, Ooi JY, Seymour JF, Keating MJ and Tam CS: Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling. Blood. 124:3829–3830. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Thompson PA, Lévy V, Tam CS, Al Nawakil C, Goudot FX, Quinquenel A, Ysebaert L, Michallet AS, Dilhuydy MS, Van Den Neste E, et al: Atrial fibrillation in CLL patients treated with ibrutinib. An international retrospective study. Br J Haematol. 175:462–466. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Lambert Kuhn E, Levêque D, Lioure B, Gourieux B and Bilbault P: Adverse event potentially due to an interaction between ibrutinib and verapamil: A case report. J Clin Pharm Ther. 41:104–105. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Mulligan SP, Ward CM, Whalley D and Hilmer SN: Atrial fibrillation, anticoagulant stroke prophylaxis and bleeding risk with ibrutinib therapy for chronic lymphocytic leukaemia and lymphoproliferative disorders. Br J Haematol. 175:359–364. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Wang ML, Blum KA, Martin P, Goy A, Auer R, Kahl BS, Jurczak W, Advani RH, Romaguera JE, Williams ME, et al: Long-term follow-up of MCL patients treated with single-agent ibrutinib: Updated safety and efficacy results. Blood. 126:739–745. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Vrontikis A, Carey J, Gilreath JA, Halwani A, Stephens DM and Sweetenham JW: Proposed algorithm for managing ibrutinib-related atrial fibrillation. Oncology (Williston Park). 30:970–974, 980-971, C973. 2016.PubMed/NCBI | |
|
Thorp BC and Badoux X: Atrial fibrillation as a complication of ibrutinib therapy: Clinical features and challenges of management. Leuk Lymphoma. 59:311–320. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
de Weerdt I, Koopmans SM, Kater AP and van Gelder M: Incidence and management of toxicity associated with ibrutinib and idelalisib: A practical approach. Haematologica. 102:1629–1639. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Jones JA, Hillmen P, Coutre S, Tam C, Furman RR, Barr PM, Schuster SJ, Kipps TJ, Flinn IW, Jaeger U, et al: Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single-agent ibrutinib. Br J Haematol. 178:286–291. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Gribben JG, Bosch F, Cymbalista F, Geisler CH, Ghia P, Hillmen P, Moreno C and Stilgenbauer S: Optimising outcomes for patients with chronic lymphocytic leukaemia on ibrutinib therapy: European recommendations for clinical practice. Br J Haematol. 180:666–679. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Levade M, David E, Garcia C, Laurent PA, Cadot S, Michallet AS, Bordet JC, Tam C, Sié P, Ysebaert L, et al: Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions. Blood. 124:3991–3995. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Lipsky AH, Farooqui MZ, Tian X, Martyr S, Cullinane AM, Nghiem K, Sun C, Valdez J, Niemann CU, Herman SE, et al: Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib. Haematologica. 100:1571–1578. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Kamel S, Horton L, Ysebaert L, Levade M, Burbury K, Tan S, Cole-Sinclair M, Reynolds J, Filshie R, Schischka S, et al: Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation. Leukemia. 29:783–787. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Dreyling M, Jurczak W, Jerkeman M, Silva RS, Rusconi C, Trneny M, Offner F, Caballero D, Joao C, Witzens-Harig M, et al: Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: An international, randomised, open-label, phase 3 study. Lancet. 387:770–778. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Yun S, Vincelette ND, Acharya U and Abraham I: Risk of atrial fibrillation and bleeding diathesis associated with ibrutinib treatment: A systematic review and pooled analysis of four randomized controlled trials. Clin Lymphoma Myeloma Leuk. 17:31–37.e13. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Treon SP, Tripsas CK, Meid K, Warren D, Varma G, Green R, Argyropoulos KV, Yang G, Cao Y, Xu L, et al: Ibrutinib in previously treated Waldenströms macroglobulinemia. N Engl J Med. 372:1430–1440. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Serebruany VL, Malinin AI, Ferguson JJ, Vahabi J, Atar D and Hennekens CH: Bleeding risks of combination vs. single antiplatelet therapy: a meta-analysis of 18 randomized trials comprising 129314 patients. Fundam Clin Pharmacol. 22:315–321. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Shatzel JJ, Olson SR, Tao DL, McCarty OJT, Danilov AV and DeLoughery TG: Ibrutinib-associated bleeding: Pathogenesis, management and risk reduction strategies. J Thromb Haemost. 15:835–847. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Dubovsky JA, Beckwith KA, Natarajan G, Woyach JA, Jaglowski S, Zhong Y, Hessler JD, Liu TM, Chang BY, Larkin KM, et al: Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood. 122:2539–2549. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Ghosh S, Bienemann K, Boztug K and Borkhardt A: Interleukin-2-inducible T-cell kinase (ITK) deficiency - clinical and molecular aspects. J Clin Immunol. 34:892–899. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Kreiniz N, Bejar J, Polliack A and Tadmor T: Severe pneumonia associated with ibrutinib monotherapy for CLL and lymphoma. Hematol Oncol. 2017.PubMed/NCBI | |
|
Issa N, Arbona-Haddad E, Nevett-Fernandez A, Prestes D, Liakos A, Woolley A, Hammond S, Brown J, Baden L and Marty F: Opportunistic infections (OIs) in patients with hematologic malignancies (HM) treated with Bruton's tyrosine kinase (BTK) and phosphoinositide 3 kinase (PI3K) inhibitors: An 8-year retrospective cohort study. Open Forum Infect Dis. 4 (Suppl_1):S6992017. View Article : Google Scholar : | |
|
Chan TS, Au-Yeung R, Chim CS, Wong SC and Kwong YL: Disseminated fusarium infection after ibrutinib therapy in chronic lymphocytic leukaemia. Ann Hematol. 96:871–872. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Ahn IE, Jerussi T, Farooqui M, Tian X, Wiestner A and Gea-Banacloche J: Atypical Pneumocystis jirovecii pneumonia in previously untreated patients with CLL on single-agent ibrutinib. Blood. 128:1940–1943. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Lionakis MS, Dunleavy K, Roschewski M, Widemann BC, Butman JA, Schmitz R, Yang Y, Cole DE, Melani C, Higham CS, et al: Inhibition of B cell receptor signaling by ibrutinib in orimary CNS lymphoma. Cancer Cell. 31:833–843.e835. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Diamantopoulos PT, Psichogiou M, Pantazatou A, Zervakis K, Rougala N, Giannakopoulou N, Daikos G and Viniou NA: Staphylococcus aureus meningitis in a patient with mantle cell lymphoma under treatment with ibrutinib. Ann Hematol. 96:1049–1050. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Tillman BF, Pauff JM, Satyanarayana G, Talbott M and Warner JL: Systematic review of infectious events with the Bruton tyrosine kinase inhibitor ibrutinib in the treatment of hematologic malignancies. Eur J Haematol. 2017. | |
|
Varughese T, Taur Y, Cohen N, Palomba ML, Seo SK, Hohl TM and Redelman-Sidi G: Serious infections in patients receiving ibrutinib for treatment of lymphoid cancer. Clin Infect Dis. 67:687–692. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Ghez D, Calleja A, Protin C, Baron M, Ledoux MP, Damaj G, Dupont M, Dreyfus B, Ferrant E, Herbaux C, et al French Innovative Leukemia Organization (FILO) CLL group, : Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib. Blood. 131:1955–1959. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Wang SY, Ebert T, Jaekel N, Schubert S, Niederwieser D and Al-Ali HK: Miliary tuberculosis after initiation of ibrutinib in chronic lymphocytic leukemia. Ann Hematol. 94:1419–1420. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Sun C, Tian X, Lee YS, Gunti S, Lipsky A, Herman SE, Salem D, Stetler-Stevenson M, Yuan C, Kardava L, et al: Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib. Blood. 126:2213–2219. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Yin Q, Sivina M, Robins H, Yusko E, Vignali M, OBrien S, Keating MJ, Ferrajoli A, Estrov Z, Jain N, et al: Ibrutinib therapy Increases T cell repertoire diversity in patients with chronic lymphocytic leukemia. J Immunol. 198:1740–1747. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Yeo W, Chan TC, Leung NW, Lam WY, Mo FK, Chu MT, Chan HL, Hui EP, Lei KI, Mok TS, et al: Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol. 27:605–611. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Yeo W and Johnson PJ: Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology. 43:209–220. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
de Jésus Ngoma P, Kabamba B, Dahlqvist G, Sempoux C, Lanthier N, Shindano T, Van Den Neste E and Horsmans Y: Occult HBV reactivation induced by ibrutinib treatment: A case report. Acta Gastroenterol Belg. 78:424–426. 2015.PubMed/NCBI | |
|
Herishanu Y, Katchman H and Polliack A: Severe hepatitis B virus reactivation related to ibrutinib monotherapy. Ann Hematol. 96:689–690. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Tedeschi A, Frustaci AM, Mazzucchelli M, Cairoli R and Montillo M: Is HBV prophylaxis required during CLL treatment with ibrutinib? Leuk Lymphoma. 58:2966–2968. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, Jurczak W, Advani RH, Romaguera JE, Williams ME, et al: Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 369:507–516. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Ujjani CS, Jung SH, Pitcher B, Martin P, Park SI, Blum KA, Smith SM, Czuczman M, Davids MS, Levine E, et al: Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103. Blood. 128:2510–2516. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Mannis G, Wu D, Dea T, Mauro T and Hsu G: Ibrutinib rash in a patient with 17p del chronic lymphocytic leukemia. Am J Hematol. 90:1792015. View Article : Google Scholar : PubMed/NCBI | |
|
Jensen AB, Stausbøl-Grøn B, Riber-Hansen R and dAmore F: Ibrutinib-associated skin toxicity: A case of maculopapular rash in a 79-year old Caucasian male patient with relapsed Waldenstroms macroglobulinemia and review of the literature. Dermatol Rep. 9:69762017. View Article : Google Scholar | |
|
Iberri DJ, Kwong BY, Stevens LA, Coutre SE, Kim J, Sabile JM and Advani RH: Ibrutinib-associated rash: A single-centre experience of clinicopathological features and management. Br J Haematol. 2016.PubMed/NCBI | |
|
Neffendorf JE, Gout I and Hildebrand GD: Ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 369:1277–1279. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Wallace N, Wong E, Cooper D and Chao H: A case of new-onset cardiomyopathy and ventricular tachycardia in a patient receiving ibrutinib for relapsed mantle cell lymphoma. Clin Case Rep. 4:1120–1121. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Lutz M, Schulze AB, Rebber E, Wiebe S, Zoubi T, Grauer OM, Keßler T, Kerkhoff A, Lenz G and Berdel WE: Progressive multifocal leukoencephalopathy after ibrutinib therapy for chronic lymphocytic leukemia. Cancer Res Treat. 49:548–552. 2017. View Article : Google Scholar : PubMed/NCBI |
